The treatment of mCRC has become increasingly complex in the past decade because of the rapid proliferation of new chemotherapies and biological therapies.
Neoadjuvant therapy for rectal cancer. Opinions from Oncology and Radiology experts.
Dr Brown developed staging criteria for colon and rectal cancer, as well as, standards for reporting that are now adopted globally. She also developed the UK Deferral of Surgery trial protocol for rectal cancer patients in response to their desires to avoid permanent stoma. She defined post-radiotherapy MRI criteria to identify complete responders eligible for […]
Preoperative chemoradiation (CT/RT) followed by surgery has been the standard of care in USA/Europe for all patients with clinical stage II and III rectal cancer. New advances to adapt our behavior.
Different points of view about a particular clinical case. Expert recommendations.
Patients suspected of having hereditary colorectal cancer syndromes should be referred for genetic counseling and, if appropriate, for genetic testing.
Pathologists play a key role in the evaluation of these specimens, including the quality assurance of surgical performance, which benefits both the surgeon and the patient.
The combination of FDG PET and CT has revolutionized the evaluation of colorectal cancer in terms of staging and restaging, accurately assessing, response to therapy, and surveillance of the patient.
Transrectal EUS is increasingly being used for locoregional staging of rectal cancer. The accuracy of EUS for the T staging of rectal carcinoma ranges from 80-95%. Accurate staging of rectal cancer is essential for selecting patients who can undergo sphincter-preserving surgery.
A direct vision of the tumor, a better identification of the mesorectal planes and a cleaner cut of the distal rectum, make easier to complete a perfect TME bottom up.